<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   MRI of the breast and emerging technologies
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       MRI of the breast and emerging technologies
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        MRI of the breast and emerging technologies
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Priscilla J Slanetz, MD, MPH, FACR
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anees B Chagpar, MD, MSc, MA, MPH, MBA, FACS, FRCS(C)
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joann G Elmore, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gary J Whitman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sadhna R Vora, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 24, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1930667">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Magnetic resonance imaging (MRI) of the breast is an important tool for the detection of breast cancer  (
         <a class="graphic graphic_diagnosticimage graphicRef86202" href="/z/d/graphic/86202.html" rel="external">
          image 1
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef86203" href="/z/d/graphic/86203.html" rel="external">
          image 2
         </a>
         ) and assessment of silicone implant integrity  (
         <a class="graphic graphic_diagnosticimage graphicRef58055" href="/z/d/graphic/58055.html" rel="external">
          image 3
         </a>
         ). The use of MRI with contrast agents for the detection of breast cancer was first reported in 1986 [
         <a href="#rid1">
          1
         </a>
         ]. The high sensitivity of MRI for breast cancer has led to the increasing use of MRI for breast cancer detection, assessment, and treatment monitoring, although appropriate indications, scanning techniques and interpretations remain variable among facilities.
        </p>
        <p>
         This topic will review breast MRI techniques, interpretation, and indications as well as emerging tools for breast cancer detection. Issues regarding screening for breast cancer, the role of mammography and ultrasound in women with suspected disease, surveillance for patients with known breast cancer, and the physics of MRI are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7561.html" rel="external">
          "Breast imaging for cancer screening: Mammography and ultrasonography"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7564.html" rel="external">
          "Screening for breast cancer: Strategies and recommendations"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/744.html" rel="external">
          "Clinical features, diagnosis, and staging of newly diagnosed breast cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5309.html" rel="external">
          "Principles of magnetic resonance imaging"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15781.html" rel="external">
          "Approach to the patient following treatment for breast cancer", section on 'Breast MRI'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10606309">
         <span class="h1">
          BREAST MRI TECHNIQUE
         </span>
         <span class="headingEndMark">
          —
         </span>
         MRI creates images of the breast by measuring changes in the movement of protons in fat and water with the application of changing magnetic fields. By utilizing the differences in tissue relaxation characteristics, an image is acquired by processing the signal changes that occur following application of pulses of energy. The physics of MRI is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5309.html" rel="external">
          "Principles of magnetic resonance imaging", section on 'Magnetic resonance physics'
         </a>
         .)
        </p>
        <p>
         Breast MRI for the detection of breast cancer requires administration of the contrast agent gadolinium. The use of MRI for breast cancer detection is based on the concept of tumor angiogenesis or neovascularity. Tumor-associated blood vessels have increased permeability, which leads to prompt uptake and release of gadolinium within the first one to two minutes after administration, leading to a pattern of rapid enhancement and washout on MRI  (
         <a class="graphic graphic_figure graphicRef74017" href="/z/d/graphic/74017.html" rel="external">
          figure 1
         </a>
         ). This dynamic rapid enhancement pattern helps to distinguish breast cancers from benign lesions. Breast MRI techniques continue to evolve, but some general recommendations can be made based on minimum standards used by the American College of Radiology Imaging Network (ACRIN) 6667 Trial [
         <a href="#rid2">
          2
         </a>
         ] and the European Society of Breast Imaging [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bilateral breast examination
         </strong>
         – Both breasts should be evaluated in an MRI study, for comparison purposes, even when concern about possible pathology involves only one breast.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Magnet
         </strong>
         – The magnet field strength recommended for breast MRI is ≥1.5-Tesla. High-field-strength magnets (3-Tesla and 7-Tesla) provide higher signal-to-noise ratios than conventional breast MRI, performed with 1.5-Tesla-field-strength magnets. The high-field-strength magnets result in higher spatial resolution and improved detection of breast cancers &lt;5 mm in size compared with conventional techniques [
         <a href="#rid4">
          4-7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Coil
         </strong>
         – A dedicated breast coil should be used for breast MRI. The breast coil is designed to receive signals generated from breast tissue and permits imaging of both breasts simultaneously. Surface coils are necessary to achieve adequate spatial resolution while maintaining high signal-to-noise levels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Positioning
         </strong>
         – Patients are placed in the prone position, over the breast coil, which has openings for the patient’s breasts. The coils surround the breasts and detect the magnetic signals from the breast. Some centers image the patient with the breasts in mild compression, which minimizes motion artifact and aids in biopsy planning.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient comfort
         </strong>
         – Patients are given ear plugs before the exam begins to help diminish the loud "knocking" sounds that are typically heard during an MRI exam. Claustrophobia can be diminished with a short-acting anxiolytic prior to the exam.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contrast
         </strong>
         – Intravenous gadolinium contrast must be used to maximize cancer detection and is administered before breast MRI to highlight the neovascularity associated with cancers. Contrast is
         <strong>
          not
         </strong>
         necessary when the study is performed to evaluate silicone implant integrity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Allergic and anaphylactoid reactions to gadolinium are rare, but can occur. In addition, in patients with renal failure, gadolinium can cause contrast nephropathy and/or nephrogenic systemic fibrosis. (See
         <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">
          "Patient evaluation before gadolinium contrast administration for magnetic resonance imaging"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A few studies have also reported gadolinium deposition in the brain from repeated intravenous administration, with the degree of deposition varying based on the specific contrast agent. The clinical significance of this deposition remains unknown, and no data for humans exist to show any adverse effects at this time [
         <a href="#rid8">
          8,9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imaging
         </strong>
         – Images are acquired within 45 seconds of contrast injection and then every one to two minutes with completion within four minutes in order to observe the early preferential signal enhancement associated with the hypervascularity of malignant tumors. Slice thickness should be ≤3 mm.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         After the first few minutes following contrast injection, benign breast tissue may also enhance. This time constraint means that a compromise must be reached between temporal and spatial resolution. Imaging strategies such as high spatial resolution and the use of fat-suppression techniques improve the sensitivity of breast MRI for small or multifocal lesions, but also increase scan times [
         <a href="#rid10">
          10,11
         </a>
         ]. Dynamic techniques, in which images are acquired at intervals of one minute or less, achieve higher temporal resolution and improve specificity by allowing the time course of contrast uptake to be better defined [
         <a href="#rid12">
          12-14
         </a>
         ]. Alternative approaches combine low temporal resolution kinetic information with high spatial resolution anatomic information as a means of achieving high sensitivity and specificity in a single-scan technique [
         <a href="#rid15">
          15-18
         </a>
         ]. Most centers compromise by acquiring temporal resolution at 1 to 1 minute 30 seconds with higher spatial resolution.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1930682">
         <span class="h1">
          MRI INTERPRETATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Breast MR images are analyzed and reported according to the standardized Breast Imaging Reporting and Data System (BI-RADS) reporting system [
         <a href="#rid19">
          19
         </a>
         ]. The report describes overall breast composition (density and background parenchymal enhancement) and specific lesions.
        </p>
        <p class="headingAnchor" id="H1349912728">
         <span class="h2">
          Breast composition
         </span>
         <span class="headingEndMark">
          —
         </span>
         The breast composition is assessed overall and is categorized by tissue composition (ie, amount of fibroglandular tissue) and by the level of background parenchymal enhancement. Background parenchymal enhancement is the degree to which normal fibroglandular tissue enhances with contrast, versus breast density, which is not dependent on contrast administration.
        </p>
        <p>
         Background parenchymal enhancement may be associated with future invasive breast cancer risk [
         <a href="#rid20">
          20
         </a>
         ]. In a multicenter study of 4247 women among whom 176 developed in situ or invasive breast cancer over a median follow-up of 2.8 years, mild, moderate, and marked background parenchymal enhancement was associated with increased cancer risk with hazard ratios (HRs) of 1.8 (95% CI 1.1-2.90), 2.4 (95% CI 1.5-3.9), and 3.4 (95% CI 2.1-5.7), respectively. For the subgroup of invasive cancer, combined mild, moderate, and marked background parenchymal enhancement was again associated with an increased risk (HR 2.7, 95% CI 1.7-4.5). The risk of a future invasive breast cancer diagnosis associated with increased background parenchymal enhancement is independent of breast density.
        </p>
        <p class="headingAnchor" id="H2837722877">
         <span class="h2">
          Lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lesions are categorized as mass or non-mass lesions. The sensitivity of breast MRI is reported as 71 to 100 percent; however, the specificity is less than 65 percent [
         <a href="#rid21">
          21,22
         </a>
         ]. The low specificity is due to the overlap in the enhancement pattern of benign and malignant lesions. Positive findings are more likely to be accurate for mass lesions than non-mass lesions [
         <a href="#rid23">
          23
         </a>
         ]. Breast MRI findings must be correlated with the patient’s mammographic and/or sonographic imaging.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mass lesions are assessed for shape, margin characteristics, and enhancement patterns. Margin characteristics, such as smooth, irregular, or spiculated margins, are significant predictors of malignant versus benign diagnoses. As with mammography, masses with irregular or spiculated margins are worrisome for malignancy. Rapid uptake and washout of gadolinium is seen more commonly in malignant lesions. Progressive enhancement over time is most often encountered in benign lesions or normal breast tissue. In one study of 266 lesions detected on breast MRI, progressive enhancement was seen with 83 percent of the benign lesions as compared with 9 percent of the malignant lesions [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Non-mass lesions are characterized by spatial distribution and patterns of enhancement within the breast. Spatial distribution can be diffuse, regional, segmental, or linear. A clumped-ring enhancement pattern is a predictor of malignant versus benign diagnoses. The non-mass lesions present substantial diagnostic challenges and account for a high percentage of false positives. As an example, in one study of 132 patients who underwent 151 biopsies for breast lesions detected on breast MRI, non-mass lesions represented only 20 percent of all lesions detected, but accounted for almost half of the false positive interpretations [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6635177">
         <span class="h3">
          MRI of high-risk breast lesions identified by core biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Breast MRI is sometimes used as an adjunct to further assess high-risk proliferative breast lesions with or without atypia, including papillomas, radial sclerosing lesions, lobular neoplasias, and atypical hyperplasias, identified by core needle biopsy [
         <a href="#rid25">
          25-27
         </a>
         ]. In a retrospective review of MRI assessment of 227 high-risk breast lesions, contrast enhancing lesions (n = 155) were significantly more likely to be associated with a breast malignancy (invasive or noninvasive) compared with nonenhancing lesions (18 versus 3 percent) [
         <a href="#rid27">
          27
         </a>
         ]. The diagnosis was confirmed by excision of the lesion. The cancer probability was also greater for non-mass lesions compared with mass lesions (43 versus 14 percent).
        </p>
        <p>
         However, the negative predictive value (NPV) is low for proliferative lesions with atypia, including lobular neoplasias (NPV 88 percent) and atypical ductal hyperplasia (NPV 90 percent) [
         <a href="#rid26">
          26
         </a>
         ]. These lesions should be excised when identified on a core needle biopsy. In comparison, the NPV for proliferative lesions without atypia (papilloma and radial scar) was 97.4 and 97.6 percent, respectively. Patients with these lesions may be safely observed with repeat annual mammographic, ultrasound or MRI imaging, depending upon patient and clinician preference. (See
         <a class="medical medical_review" href="/z/d/html/806.html" rel="external">
          "Overview of benign breast diseases", section on 'Proliferative lesions without atypia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/806.html" rel="external">
          "Overview of benign breast diseases", section on 'Proliferative lesions with atypia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H536410">
         <span class="h1">
          LIMITATIONS OF BREAST MRI
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hormonal changes and cancer treatments can affect the accuracy of breast MRIs and should be taken into account when scheduling and interpreting the study. Although there is variation in the performance of breast MRIs, reporting should follow standard guidelines. Facilities that perform breast MRI should have MRI-biopsy capability.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Menstrual cycle
         </strong>
         – To minimize the effects of physiologic glandular enhancement that accompany the menstrual cycle, premenopausal patients or patients on cyclic hormone replacement therapy can be imaged between days 5 to 15 of their cycle [
         <a href="#rid28">
          28-31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7418.html" rel="external">
          "Normal menstrual cycle"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lactation
         </strong>
         – Breast MRI during lactation is of limited value given the increased breast density and rapid diffuse enhancement that occur as a result of normal hormonal changes and interfere with accurate interpretation [
         <a href="#rid32">
          32,33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cancer treatment
         </strong>
         – Surgery and/or radiation therapy within 12 to 18 months before breast MRI can lead to increased gadolinium uptake and false positive studies [
         <a href="#rid34">
          34,35
         </a>
         ]. It is not known how recent chemotherapy impacts gadolinium uptake, although there are reports that selective estrogen receptor modulators (eg,
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         ) and aromatase inhibitors (eg, Arimidex) can cause malignancies to appear smaller or even undetectable on MRI [
         <a href="#rid36">
          36,37
         </a>
         ].
         <strong>
         </strong>
         Based upon a prospective study that included 40 women, tamoxifen, and to a lesser extent aromatase inhibitors, substantially suppress background enhancement, making it challenging to detect even benign breast lesions by MRI imaging [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          MRI reporting
         </strong>
         – Breast MRIs are increasingly reported using the Breast Imaging Reporting and Data System (BI-RADS) [
         <a href="#rid19">
          19
         </a>
         ]. The BI-RADS system was originally developed by the American College of Radiology to standardize mammography reporting, but is now also used for breast ultrasound (US) and MRI  (
         <a class="graphic graphic_table graphicRef100197" href="/z/d/graphic/100197.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid39">
          39
         </a>
         ]. However, the probability of malignancy for these assessment codes for US and MRI are not as well established, although it is believed that they are likely similar to that with mammography. (See
         <a class="medical medical_review" href="/z/d/html/7561.html" rel="external">
          "Breast imaging for cancer screening: Mammography and ultrasonography", section on 'BI-RADS final assessment categories'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Standardization
         </strong>
         – The specific sequences acquired during the examination vary between facilities [
         <a href="#rid40">
          40
         </a>
         ]. In addition, the dynamic enhancement data often are not archived with the image files. The lack of standardization in breast MRI impairs the ability to compare studies from different institutions, thus leading to repeat MRIs when patients seek second opinions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Biopsy capability
         </strong>
         – Based on current National Comprehensive Cancer Network (NCCN) guidelines, imaging centers that perform MRI should have the ability to perform MRI-guided needle sampling and/or wire localization of MRI detected findings [
         <a href="#rid41">
          41
         </a>
         ]. Almost half of abnormal findings on MRI may not be evident on other imaging studies [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cost
         </strong>
         – In the United States, MRI of the breast is expensive, costing approximately 10 to 15 times more than mammography or US, and is not uniformly reimbursed by insurance. In addition, for up to 10 percent of all women who undergo MRI, the study results in recommendation for follow up MRI in six months to reassess nonspecific, but probably benign findings.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Menopause status
         </strong>
         – Postmenopausal patients with breast cancer more commonly exhibit slow initial-phase contrast uptake and persistent enhancement on delayed imaging rather than the classic early rapid contrast uptake with washout on delayed MR sequences. In a retrospective review of 273 patients with breast cancer (153 intraductal cancers, 24 lobular cancers, and 4 mixed histology), typical kinetic findings (rapid contrast uptake) were less likely to be seen in postmenopausal patients (n = 155) compared with premenopausal (n = 110) and postmenopausal patients using hormone replacement therapy (n = 8) (56.8 versus 80.9 versus 50.0 percent) [
         <a href="#rid43">
          43
         </a>
         ]. In addition, postmenopausal women with cancers were more likely to have persistent enhancement on delayed imaging compared with premenopausal women (57 versus 46 percent).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3948722">
         <span class="h1">
          PRECAUTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Contraindications for breast MRI include pregnancy, implanted devices and foreign bodies, and any prior history of gadolinium allergy or diminished renal function. Since no guideline can cover all devices, when the safety of particular devices is being considered, readers are referred to safety information for specific devices which is compiled on dedicated web sites (
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.mrisafety.com%2F&amp;token=qakz4PgWrbZzs7hmTG4CDyr%2F%2FDjoo8ckBsfXhvIP%2F9kbbIIv8gdHfFDc9mGyBJhj&amp;TOPIC_ID=14972" target="_blank">
          www.MRIsafety.com
         </a>
         ) and, when available, manufacturer's product information [
         <a href="#rid44">
          44
         </a>
         ]. The contraindications for MRI are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/113084.html" rel="external">
          "Patient evaluation for metallic or electrical implants, devices, or foreign bodies before magnetic resonance imaging", section on 'Assessing implants, devices, or foreign bodies for MRI'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H633667">
         <span class="h1">
          INDICATIONS FOR BREAST MRI
         </span>
         <span class="headingEndMark">
          —
         </span>
         The appropriate use of breast MRI is established for certain indications, while others are still being investigated. Breast MRI has been used for the assessment of silicone implant integrity, diagnosis of occult primary breast cancers, determination of disease extent in newly diagnosed breast cancer patients (when indicated), documentation of response to neoadjuvant chemotherapy, diagnosis of recurrence, clarification of inconclusive clinical or mammographic findings, and screening of high-risk patients.
        </p>
        <p class="headingAnchor" id="H633682">
         <span class="h2">
          Assessment of breast implants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Breast MRI is useful for detection of silicone implant rupture and diagnosis of masses caused by free silicone injections. There is no role for breast MRI in
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         implant assessment.
        </p>
        <p class="headingAnchor" id="H633704">
         <span class="h3">
          Silicone implants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most silicone implants have a shell around the actual implant capsule; hence implant ruptures are described as intracapsular or extracapsular [
         <a href="#rid45">
          45
         </a>
         ]. Intracapsular ruptures are defined as rupture of the silicone shell or envelope around the liquid silicone, with an intact fibrous capsule. Extracapsular ruptures are defined as rupture of both the envelope and fibrous capsule, allowing leakage into the surrounding tissue. Both types of rupture usually require surgical removal of the implant. Surgical excision of an extracapsular rupture is technically more challenging because of the silicone leakage into the surrounding tissue.
        </p>
        <p>
         Breast MRI is the most useful imaging test for detecting both intracapsular and extracapsular ruptures of a silicone breast implant with a sensitivity and specificity of over 90 percent  (
         <a class="graphic graphic_diagnosticimage graphicRef53026" href="/z/d/graphic/53026.html" rel="external">
          image 4
         </a>
         ) [
         <a href="#rid45">
          45-49
         </a>
         ]. The most reliable sign of rupture on MRI is the presence of multiple curvilinear lines, which represent the collapsed implant shell floating inside the silicone gel, referred to as the "linguine sign."
        </p>
        <p>
         The most important risk factor for silicone breast implant rupture is time since placement, since 50 percent of implants rupture after 12 years [
         <a href="#rid50">
          50
         </a>
         ]. The United States Food and Drug Administration (FDA) recommends that regular MRI screening be performed for asymptomatic women with silicone implants five years after implantation and every two to three years thereafter [
         <a href="#rid51">
          51
         </a>
         ]. However, there is little evidence to support a recommendation for regular MRI screening, which is expensive and may lead to anxiety and false positive results, and result in unnecessary surgery. Therefore, most experts agree that breast MRI should be used as a confirmatory diagnostic test and not be used to screen asymptomatic women for implant rupture [
         <a href="#rid51">
          51,52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H633711">
         <span class="h3">
          Free silicone injections
         </span>
         <span class="headingEndMark">
          —
         </span>
         Direct injection of liquid silicone into the breast tissue for breast augmentation was done in the 1950’s [
         <a href="#rid53">
          53,54
         </a>
         ]. This practice led to the development of painful hard silicone masses in the breast, termed silicone granulomas or siliconomas. Although this practice was banned by the FDA in the United States in 1965, free silicone injections are still performed in other countries and women may present with sequelae of this technique [
         <a href="#rid54">
          54
         </a>
         ]. Breast MRI is helpful in differentiating siliconomas from other breast masses because most silicone masses do not enhance with contrast administration.
        </p>
        <p class="headingAnchor" id="H376067">
         <span class="h3">
          Saline implants
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no role for breast MRI imaging to detect rupture of
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         implants, as rupture results in rapid deflation of the implant and is easily detected on physical examination and/or mammography. (See
         <a class="medical medical_review" href="/z/d/html/7564.html" rel="external">
          "Screening for breast cancer: Strategies and recommendations", section on 'Breast augmentation for benign reasons'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3949769">
         <span class="h2">
          Detection of occult primary breast cancer in women with axillary metastases
         </span>
         <span class="headingEndMark">
          —
         </span>
         Breast MRI is useful for detection of an occult primary breast cancer when a patient presents with metastatic disease in the axillary lymph nodes with no evident primary breast lesion. Several observational series have demonstrated that breast MRI can detect a primary breast cancer in the majority of women who present with axillary adenocarcinoma  (
         <a class="graphic graphic_table graphicRef62800" href="/z/d/graphic/62800.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef58055" href="/z/d/graphic/58055.html" rel="external">
          image 3
         </a>
         ) [
         <a href="#rid22">
          22,41,55-66
         </a>
         ]. The evaluation and treatment of women with occult primary breast cancer is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/766.html" rel="external">
          "Axillary node metastases with occult primary breast cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10606323">
         <span class="h2">
          Preoperative evaluation of newly diagnosed breast cancer patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although many invasive breast carcinomas enhance on gadolinium-enhanced breast MRI [
         <a href="#rid1">
          1,10,11,15,22,67-76
         </a>
         ], including occult and contralateral lesions  (
         <a class="graphic graphic_diagnosticimage graphicRef64751" href="/z/d/graphic/64751.html" rel="external">
          image 5
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef76575" href="/z/d/graphic/76575.html" rel="external">
          image 6
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef55600 graphicRef82069" href="/z/d/graphic/55600.html" rel="external">
          image 7A-B
         </a>
         ), routine use of preoperative breast MRI has not clearly demonstrated either surgical or outcomes benefits. A preoperative breast MRI for women who carry a deleterious mutation in breast cancer susceptibility gene 1 (
         <em>
          BRCA1
         </em>
         ), breast cancer susceptibility gene 2 (
         <em>
          BRCA2
         </em>
         ), or other high-risk genetic syndromes may be useful for detection of an ipsilateral or contralateral cancer (see
         <a class="medical medical_review" href="/z/d/html/785.html" rel="external">
          "Overview of hereditary breast and ovarian cancer syndromes"
         </a>
         ). Almost half of abnormal findings on MRI may not be evident on other imaging studies.
        </p>
        <p>
         Based upon a meta-analysis of four studies that included 3180 affected breasts and 3169 patients, there was no difference in the rate of local recurrence at eight years for patients receiving a preoperative breast MRI compared with those without preoperative imaging (97 versus 95 percent) [
         <a href="#rid77">
          77
         </a>
         ]. In addition, there was no difference in eight-year disease-free survival for those managed with a preoperative MRI (89 versus 93 percent).
        </p>
        <p>
         By contrast, in a subsequent retrospective review of 2483 patients diagnosed with invasive breast cancer in the Netherlands, on multivariable regression analyses, preoperative MRI was associated with a reduced risk of positive resection margins after breast-conserving surgery (adjusted odds ratio [OR] 0.56, 95% CI 0.33-0.96) [
         <a href="#rid78">
          78
         </a>
         ]. However, based upon a retrospective review of the Surveillance, Epidemiology, and End-Result-Medicare database that included 45,453 women diagnosed with early stage breast cancer, and after adjusting for patient and cancer characteristics, a preoperative breast MRI did not reduce the incidence of multiple breast cancer related operations [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
         Major disadvantages of breast MRI are its limited specificity due to enhancement of benign breast lesions, which can lead to additional and unnecessary biopsies and a slightly higher rate of contralateral mastectomies in some studies [
         <a href="#rid80">
          80-82
         </a>
         ], as well as delays in regional and/or systemic treatment. Other studies have shown an increase in contralateral mastectomy rate independent of the use of preoperative breast MRI [
         <a href="#rid83">
          83,84
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94744.html" rel="external">
          "Contralateral prophylactic mastectomy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5021462">
         <span class="h2">
          Evaluation of a suspected breast cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         A breast MRI may be helpful in the clinical setting of a questionable clinical or mammographic/ultrasonic examination in a patient who is not an operative candidate. (See
         <a class="medical medical_review" href="/z/d/html/808.html" rel="external">
          "Diagnostic evaluation of suspected breast cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10606330">
         <span class="h2">
          Measurement of response to neoadjuvant chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neoadjuvant systemic therapy, also referred to as primary or preoperative systemic therapy, is the accepted approach for women with locally advanced breast cancer to reduce the size of the cancer and possibly allow for breast conservation. In most cases, response to treatment can be assessed with physical examination, which may be supplemented, in some cases, by the breast imaging technique that most clearly showed the cancer at the time of diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/14225.html" rel="external">
          "General principles of neoadjuvant management of breast cancer", section on 'Clinical assessment and indications for imaging'
         </a>
         .)
        </p>
        <p>
         There is increased interest in using breast MRI for assessment of the response to chemotherapy since decreases in lesion size and changes in enhancement kinetics correlate with pathologic response  (
         <a class="graphic graphic_diagnosticimage graphicRef63203" href="/z/d/graphic/63203.html" rel="external">
          image 8
         </a>
         ) [
         <a href="#rid85">
          85-89
         </a>
         ]. However, MRI has been shown to both overestimate and underestimate the amount of residual tumor after neoadjuvant chemotherapy [
         <a href="#rid89">
          89
         </a>
         ]. For patients receiving neoadjuvant therapy, assessment of cancer enhancement patterns, tumor distribution patterns, tumor size, and background enhancement may improve the MRI specificity to monitor cancer response to therapy [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
         A trial sponsored by the American College of Radiology Imaging Network (ACRIN) study 6657 is underway to study the use of MRI for the assessment of response to neoadjuvant chemotherapy [
         <a href="#rid91">
          91
         </a>
         ]. Indications for neoadjuvant chemotherapy and the evaluation of response to treatment are discussed elsewhere.
        </p>
        <p class="headingAnchor" id="H10606337">
         <span class="h2">
          Differentiating postoperative changes from recurrence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 10 to 15 percent of patients with breast cancer will develop a locoregional recurrence within 10 years of treatment with breast conserving therapy. Breast MRI can be used to differentiate surgical scarring and radiation changes from breast cancer recurrence in cases where the physical examination and imaging with mammography and/or ultrasound (US) is difficult to interpret  (
         <a class="graphic graphic_diagnosticimage graphicRef74918" href="/z/d/graphic/74918.html" rel="external">
          image 9
         </a>
         ) [
         <a href="#rid21">
          21,92-94
         </a>
         ]. Enhancement in the prior surgical site is suggestive of recurrence and merits core biopsy, while the absence of enhancement in the biopsy bed suggests fibrosis [
         <a href="#rid95">
          95
         </a>
         ]. However, false positive readings can result from fat necrosis which also can enhance avidly.
        </p>
        <p>
         The recommendations for post-treatment surveillance and the management of locoregional recurrence after breast conserving therapy are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/128421.html" rel="external">
          "Surgery and radiation for locoregional recurrences of breast cancer", section on 'Management of in-breast recurrence following BCT'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15781.html" rel="external">
          "Approach to the patient following treatment for breast cancer", section on 'Breast MRI'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10606351">
         <span class="h2">
          Evaluation of inconclusive clinical or imaging findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Breast MRI can be used for the evaluation of equivocal findings on conventional imaging with mammography and US, such as focal asymmetry or a mammographic abnormality seen on only one view  (
         <a class="graphic graphic_diagnosticimage graphicRef54454" href="/z/d/graphic/54454.html" rel="external">
          image 10
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef69798 graphicRef55041" href="/z/d/graphic/69798.html" rel="external">
          image 11A-B
         </a>
         ) [
         <a href="#rid96">
          96
         </a>
         ]. MRI may be helpful as an adjunct study to provide guidance for targeted US or core biopsy when localization would be difficult with conventional imaging alone. However, a negative MRI does not obviate the need for biopsy for suspicious findings on conventional imaging or physical examination [
         <a href="#rid15">
          15,97
         </a>
         ].
        </p>
        <p>
         There is no data to support the use of breast MRI to evaluate patients with breast pain or patients with palpable lumps who have had normal mammography and sonography. Suspicious palpable breast lumps require biopsy for diagnosis. Conventional breast imaging techniques, the evaluation of breast pain and breast lumps, and the diagnostic approach to women with suspected breast cancer are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7561.html" rel="external">
          "Breast imaging for cancer screening: Mammography and ultrasonography"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/803.html" rel="external">
          "Breast pain"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/804.html" rel="external">
          "Clinical manifestations, differential diagnosis, and clinical evaluation of a palpable breast mass"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/808.html" rel="external">
          "Diagnostic evaluation of suspected breast cancer"
         </a>
         .)
        </p>
        <p>
         Breast MRI for the evaluation of spontaneous nipple discharge when mammography and US of the periareolar area fail to identify a focal finding [
         <a href="#rid97">
          97-102
         </a>
         ] can sometimes help guide biopsy or surgery, but the gold standard for pathologic nipple discharge remains terminal duct excision. The evaluation and treatment of nipple discharge is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/802.html" rel="external">
          "Nipple discharge"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10606358">
         <span class="h2">
          Screening high-risk women
         </span>
         <span class="headingEndMark">
          —
         </span>
         MRI has higher sensitivity for the detection of breast cancer in the high-risk population than mammography or US and thus is used for screening women who are at significantly high risk for the development of breast cancer  (
         <a class="graphic graphic_diagnosticimage graphicRef82565" href="/z/d/graphic/82565.html" rel="external">
          image 12
         </a>
         ) [
         <a href="#rid22">
          22,103-112
         </a>
         ]. This is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7564.html" rel="external">
          "Screening for breast cancer: Strategies and recommendations", section on 'High risk: Screening'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10606365">
         <span class="h1">
          EMERGING IMAGING TECHNOLOGY FOR BREAST CANCER DETECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recognition of the limitations of mammography, ultrasound (US), and breast MRI has led to investigation of other breast imaging techniques including abbreviated breast MRI protocols, contrast-enhanced dual energy digital mammography, high-field strength MRI, magnetic resonance spectroscopy, diffusion weighted imaging, breast-specific gamma imaging, and positron emission mammography.
        </p>
        <p class="headingAnchor" id="H716236411">
         <span class="h2">
          Abbreviated breast MRI protocols
         </span>
         <span class="headingEndMark">
          —
         </span>
         Abbreviated breast MRI for breast cancer screening consists of a shortened imaging protocol such that patients are on the MRI scanner for no more than 5 to 10 minutes in total, as compared with 15 to 20 minutes for a full diagnostic study. There are a few retrospective studies in women with variable risk profiles and breast density that have shown that the abbreviated MRI protocol has comparable sensitivity with the full diagnostic protocol [
         <a href="#rid113">
          113-117
         </a>
         ]. In addition, one study in women with prior breast surgery showed that when an abbreviated MRI protocol was compared with screening breast US and mammography, the MRI detected all 12 cancers, 7 of which were not detected on the other modalities, suggesting that abbreviated MRI may eventually have a role in screening women at increased risk for breast cancer [
         <a href="#rid118">
          118
         </a>
         ]. In a separate retrospective study, among 475 women of average risk with dense breasts and negative digital breast tomosynthesis, supplemental abbreviated breast MRI resulted in a clinical detection rate of 27.4 per 1000 women [
         <a href="#rid119">
          119
         </a>
         ]. However, at present, despite these promising results, most insurers do not cover supplemental MRI screening for women of average risk with dense breasts.
        </p>
        <p class="headingAnchor" id="H2782056">
         <span class="h2">
          Contrast-enhanced dual-energy digital mammography
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bilateral dual-energy (DE) contrast-agent-enhanced (CE) digital mammography is a technique for detecting breast cancer that consists of high-energy and low-energy digital mammography following an intravenous injection of an iodinated contrast material [
         <a href="#rid120">
          120
         </a>
         ]. This technology may be a useful adjunct for patients who cannot undergo MRI evaluation (eg, claustrophobic, pacemaker), as studies have shown comparable sensitivity [
         <a href="#rid121">
          121
         </a>
         ].
        </p>
        <p>
         The following studies illustrate the benefits of contrast-enhanced mammography:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective study that included 52 patients with a newly diagnosed breast cancer who underwent conventional mammography and an MRI followed by DE CE mammography found that MRI and DE CE mammography detected 50 (96 percent) of the index tumors [
         <a href="#rid122">
          122
         </a>
         ]. Conventional mammography detected 42 cancers (81 percent). MRI detected 22 of 25 (88 percent) additional ipsilateral cancers while DE CE mammography detected 14 cancers (56 percent). An enhancing lesion identified on DE CE mammography was more likely to be malignant compared with enhancing lesions identified by MRI (positive predictive value 97 versus 85 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective study of 89 women with dense breast tissue that included 72 malignancies and 28 benign lesions found that CE subtracted mammography increased the rate of cancer detection (specificity) compared with conventional mammography (92.7 versus 71.5 percent) [
         <a href="#rid123">
          123
         </a>
         ]. In addition, CE subtracted mammography also improved specificity (67.9 versus 51.8 percent) and accuracy of diagnosis (85.8 versus 65.9 percent).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10606388">
         <span class="h2">
          Magnetic resonance spectroscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         MR spectroscopy is a specialized MRI sequence that allows assessment of the chemical composition of tissue. Breast MR spectroscopy is designed to detect choline and its derivatives, based on the observation that malignant tumors have elevated choline levels [
         <a href="#rid96">
          96,124
         </a>
         ]. Choline is a molecule required for fatty acid synthesis during cell membrane production.
        </p>
        <p>
         MR spectroscopy may provide an adjunct to conventional breast MRI, with the potential to increase specificity and avoid benign biopsies in a substantial number of women. MR spectroscopy is also promising for the evaluation of non-mass like suspicious findings on breast MRI [
         <a href="#rid125">
          125
         </a>
         ].
         <strong>
         </strong>
         However, MR spectroscopy misses some breast cancers, because not all express choline. In a study of 16 invasive ductal tumors; 88 percent had detectable choline peaks [
         <a href="#rid126">
          126
         </a>
         ]. MR spectroscopy remains investigational, but it may have a future role in predicting outcome and monitoring response of therapy [
         <a href="#rid127">
          127,128
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10606395">
         <span class="h2">
          Diffusion weighted imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diffusion weighted imaging is a noninvasive imaging technique that assesses the random motion of the water molecules in tissue, based on the observation that water diffusion is abnormal in breast cancers. The signal strength of water molecules is proportional to the degree of diffusion. The results of diffusion-weighted imaging are calculated and then reported with a quantitative measure termed the apparent diffusion coefficient (ADC) for the tissue being studied.
        </p>
        <p>
         Invasive breast cancers demonstrate restricted or less water diffusion than normal breast tissue or benign breast lesions, which results in a lower ADC [
         <a href="#rid96">
          96,129-131
         </a>
         ]. A few observational studies have shown that diffusion-weighted imaging can differentiate benign from malignant breast lesions with equal sensitivity and greater specificity than MRI [
         <a href="#rid132">
          132-134
         </a>
         ].
        </p>
        <p>
         While diffusion weighted imaging is promising for use in preoperative assessment of disease extent in breast cancer patients, the available data is limited and this technique cannot be used for screening asymptomatic women or to exclude breast cancer in patients with suspicious breast masses or abnormal mammography [
         <a href="#rid135">
          135,136
         </a>
         ]. However, a retrospective review of 101 women (20 malignant, 84 benign breast lesions) undergoing additional DWI found that DWI at the time of breast MRI can reduce the number of MRI-guided false positive or benign biopsies by 34.5 percent without false-negative findings [
         <a href="#rid137">
          137
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10606402">
         <span class="h2">
          Nuclear breast imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nuclear breast imaging techniques include breast-specific gamma imaging (BSGI), positron emission tomography (PET) scanning, and positron emission mammography (PEM). These techniques provide a functional assessment of breast lesions at the cellular and the metabolic levels. Nuclear imaging techniques are limited by suboptimal spatial resolution of whole body cameras, hindering detection of small lesions. However, with the development of dedicated breast units, nuclear breast imaging has the potential to detect lesions less than 1 cm in size.
        </p>
        <p>
         Nuclear breast imaging techniques are promising for indications similar to those of breast MRI, including determination of disease extent, high-risk screening, and monitoring response to therapy. However, there are limited data to justify the use of nuclear breast imaging techniques and they should be considered investigational. In addition, unlike MRI, nuclear breast imaging requires radiation exposure and radiation-related risks should be taken into consideration and discussed with the patient. (See
         <a class="medical medical_review" href="/z/d/html/14613.html" rel="external">
          "Radiation-related risks of imaging"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10606409">
         <span class="h3">
          Breast-specific gamma imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         BSGI is a nuclear medicine imaging technique, using gamma cameras with 2 to 3 mm in-plane resolution in a mammographic configuration to provide images of the breast [
         <a href="#rid138">
          138,139
         </a>
         ]. BSGI is based on the observation that breast cancers accumulate technetium-99m sestamibi in intracellular mitochondria. Intracellular mitochondria are present in greater numbers in breast cancer cells as compared to normal cells.
        </p>
        <p>
         BSGI is performed after intravenous injection of 25 mCi of technetium-99m sestamibi. The patient is imaged approximately 5 to 10 minutes following the injection of the radioisotope. Two scans are performed of each breast using mild compression for craniocaudal and mediolateral oblique views. Images should be correlated with the patient’s mammograms, breast US and clinical breast examination. If a biopsy is necessary for a lesion not seen on other imaging modalities, a BSGI-compatible biopsy system is used to direct tissue sampling.
        </p>
        <p>
         In several observational studies, BSGI demonstrated equal sensitivity and greater specificity than MRI for the detection of breast cancer [
         <a href="#rid140">
          140-145
         </a>
         ]. While BSGI is promising for use in the preoperative assessment of disease extent in breast cancer patients, the available data are limited and we do not use this technique for screening or to exclude breast cancer in patients with suspicious breast masses or abnormal mammography. We note, however, that it is used for screening at some centers.
        </p>
        <p class="headingAnchor" id="H10606416">
         <span class="h3">
          Positron emission tomography scanning
         </span>
         <span class="headingEndMark">
          —
         </span>
         PET scanning is a nuclear medicine imaging technique which produces a three-dimensional image.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fluorine-18-labeled deoxyglucose PET
         </strong>
         – PET scanning for breast cancer detection is based on increased glucose metabolism in cancer cells as compared with normal tissue; hence, malignancies can be detected with a radioactive tracer that reflects the process of increased glycolysis. A sugar, fluorine-18-labeled deoxyglucose (FDG), is used as the radioactive tracer for PET scanning because it is actively transported across the cell membrane, undergoes phosphorylation to FDG-6-phosphate, and is trapped within the cells. Tumor cells accumulate higher concentrations of the tracer than normal cells and are seen on the imaging scan as an area of enhancement.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Because glucose is used as the radioactive tracer, patients must fast for four to six hours prior to injection to minimize cardiac uptake, and avoid strenuous activity for 24 hours prior to the study to minimize skeletal muscle uptake. A high-protein, low carbohydrate diet for 24 to 48 hours prior to imaging is also recommended, in an effort to minimize myocardial uptake of glucose. The patient's serum glucose should be less than 200 mg/dL for optimal results.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         To prepare for the scan, the patient is injected intravenously with 10 to 15mCi of the isotope FDG, and allowed to rest quietly in a warm room. After the isotope circulates for 60 to 90 minutes, the imaging can be performed. Although malignancies take up the agent, false positives can result from any metabolically active process such as acute infection, radiation treatment, or trauma.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A conventional positron emission tomography (PET) device does not have the spatial resolution to reliably detect primary breast malignancies less than 1 cm in size. PET scanning, with or without computed tomography (CT) image fusion, has been utilized in selected cases for staging of breast cancer for axillary and distant metastatic disease, evaluating patients with recurrence, and monitoring response to chemotherapy [
         <a href="#rid146">
          146-150
         </a>
         ]. Routine post-treatment surveillance with PET in women treated for breast cancer is not recommended. (See
         <a class="medical medical_review" href="/z/d/html/15781.html" rel="external">
          "Approach to the patient following treatment for breast cancer", section on 'Role of laboratory evaluation and other imaging'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="128300" href="/z/d/drug information/128300.html" rel="external">
          Fluoroestradiol F-18
         </a>
         <strong>
          PET
         </strong>
         – A novel methodology, using fluoroestradiol F-18 as the radioactive diagnostic agent, is approved by the US Food and Drug Administration for the detection of estrogen receptor (ER)-positive lesions, as an adjunct to biopsy, in patients with recurrent or metastatic breast cancer [
         <a href="#rid151">
          151
         </a>
         ]. However, drugs such as
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         and
         <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">
          fulvestrant
         </a>
         block the ER and reduce the uptake of fluoroestradiol F-18. Therefore, for patients receiving this type of imaging, it should be performed prior to starting such systemic therapies. Given that aromatase inhibitors (AIs) act by impeding the production of estrogen, concurrent use of AIs during fluoroestradiol F-18 imaging is permitted.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a study involving 200 patients with newly diagnosed metastatic breast cancer,
         <a class="drug drug_general" data-topicid="128300" href="/z/d/drug information/128300.html" rel="external">
          fluoroestradiol F-18
         </a>
         PET had a sensitivity of 95 percent and a specificity of 80 percent for ER positive lesions [
         <a href="#rid152">
          152
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3198334564">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119884.html" rel="external">
          "Society guideline links: Screening for breast cancer"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/113775.html" rel="external">
          "Society guideline links: Breast cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1930703">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Magnetic resonance imaging (MRI) may be used in select circumstances for breast cancer detection, assessment, and treatment monitoring, although appropriate indications, standardization of techniques, and interpretation remain variable among facilities. MRI of the breast is also an important tool for the assessment of silicone implant integrity. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The use of MRI for breast cancer detection is based on the concept of tumor angiogenesis or neovascularity. Tumor associated blood vessels have increased permeability, which leads to prompt take up and release of the contrast agent and helps to distinguish breast cancers from benign growths. (See
         <a class="local">
          'Breast MRI technique'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A dedicated breast coil should be used for breast MRI. The breast coil is designed to receive signals generated from breast tissue and permits imaging of both breasts simultaneously. (See
         <a class="local">
          'Breast MRI technique'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intravenous gadolinium contrast must be used to maximize cancer detection and is administered during breast MRI to highlight neovascularity associated with cancers. Contrast is
         <strong>
          not
         </strong>
         necessary when the study is performed to evaluate silicone implant integrity. Gadolinium is contraindicated in patients with compromised renal function. (See
         <a class="local">
          'Breast MRI technique'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Breast MRI images are analyzed for morphology and initial and delayed contrast enhancement. Lesions are categorized as mass or non-mass lesions. The sensitivity of breast MRI is high, but the specificity is lower due to the overlap in the enhancement patterns of benign and malignant lesions. (See
         <a class="local">
          'MRI interpretation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hormonal changes and cancer treatments can affect the accuracy of breast MRIs. Although there is variation in the performance of breast MRIs, reporting should follow standard guidelines. Facilities that perform breast MRI should have MRI-biopsy capability. (See
         <a class="local">
          'Limitations of breast MRI'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Contraindications for breast MRI include pregnancy, implanted devices and foreign bodies, and any prior history of gadolinium allergy or diminished renal function. (See
         <a class="local">
          'Precautions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The appropriate use of breast MRI is evolving and some indications remain controversial. Breast MRI has been used for the assessment of silicone implant integrity, the diagnosis of occult primary breast cancers, the determination of disease extent in newly diagnosed breast cancer patients (when indicated), documentation of response to neoadjuvant chemotherapy, diagnosis of recurrence, clarification of inconclusive clinical or imaging findings, and screening of high-risk patients. (See
         <a class="local">
          'Indications for breast MRI'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recognition of the limitations of mammography, ultrasound, and breast MRI has led to investigation of other promising breast imaging techniques including high-field strength MRI, magnetic resonance spectroscopy, diffusion weighted imaging, and breast-specific gamma imaging. (See
         <a class="local">
          'Emerging imaging technology for breast cancer detection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H440138241">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Elaine Iuanow, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Heywang SH, Hahn D, Schmidt H, et al. MR imaging of the breast using gadolinium-DTPA. J Comput Assist Tomogr 1986; 10:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lehman CD, Gatsonis C, Kuhl CK, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 2007; 356:1295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeMartini WB, Ichikawa L, Yankaskas BC, et al. Breast MRI in community practice: equipment and imaging techniques at facilities in the Breast Cancer Surveillance Consortium. J Am Coll Radiol 2010; 7:878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hecht EM, Lee RF, Taouli B, Sodickson DK. Perspectives on body MR imaging at ultrahigh field. Magn Reson Imaging Clin N Am 2007; 15:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuhl CK. Breast MR imaging at 3T. Magn Reson Imaging Clin N Am 2007; 15:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elsamaloty H, Elzawawi MS, Mohammad S, Herial N. Increasing accuracy of detection of breast cancer with 3-T MRI. AJR Am J Roentgenol 2009; 192:1142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinker K, Grabner G, Bogner W, et al. A combined high temporal and high spatial resolution 3 Tesla MR imaging protocol for the assessment of breast lesions: initial results. Invest Radiol 2009; 44:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. Radiology 2015; 275:772.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gulani V, Calamante F, Shellock FG, et al. Gadolinium deposition in the brain: summary of evidence and recommendations. Lancet Neurol 2017; 16:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harms SE, Flamig DP, Hesley KL, et al. MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation. Radiology 1993; 187:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pierce WB, Harms SE, Flamig DP, et al. Three-dimensional gadolinium-enhanced MR imaging of the breast: pulse sequence with fat suppression and magnetization transfer contrast. Work in progress. Radiology 1991; 181:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubens D, Totterman S, Chacko AK, et al. Gadopentetate dimeglumine-enhanced chemical-shift MR imaging of the breast. AJR Am J Roentgenol 1991; 157:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boetes C, Barentsz JO, Mus RD, et al. MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique. Radiology 1994; 193:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hulka CA, Smith BL, Sgroi DC, et al. Benign and malignant breast lesions: differentiation with echo-planar MR imaging. Radiology 1995; 197:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bluemke DA, Gatsonis CA, Chen MH, et al. Magnetic resonance imaging of the breast prior to biopsy. JAMA 2004; 292:2735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Degani H, Gusis V, Weinstein D, et al. Mapping pathophysiological features of breast tumors by MRI at high spatial resolution. Nat Med 1997; 3:780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kinkel K, Helbich TH, Esserman LJ, et al. Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability. AJR Am J Roentgenol 2000; 175:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khatri VP, Stuppino JJ, Espinosa MH, Pollack MS. Improved accuracy in differentiating malignant from benign mammographic abnormalities: a simple, improved magnetic resonance imaging method. Cancer 2001; 92:471.
          </a>
         </li>
         <li class="breakAll">
          American College of Radiology. American College of Radiology Breast Imaging Reporting and Data System BI-RADS, 5th ed, D'Orsi CJ, Sickles EA, Mendelson EB, Morris EA, et al. (Eds), American Colege of Radiology, Reston, VA 2013.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arasu VA, Miglioretti DL, Sprague BL, et al. Population-Based Assessment of the Association Between Magnetic Resonance Imaging Background Parenchymal Enhancement and Future Primary Breast Cancer Risk. J Clin Oncol 2019; 37:954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seely JM, Nguyen ET, Jaffey J. Breast MRI in the evaluation of locally recurrent or new breast cancer in the postoperative patient: correlation of morphology and enhancement features with the BI-RADS category. Acta Radiol 2007; 48:838.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeMartini W, Lehman C. A review of current evidence-based clinical applications for breast magnetic resonance imaging. Top Magn Reson Imaging 2008; 19:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baltzer PA, Benndorf M, Dietzel M, et al. False-positive findings at contrast-enhanced breast MRI: a BI-RADS descriptor study. AJR Am J Roentgenol 2010; 194:1658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuhl CK, Mielcareck P, Klaschik S, et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 1999; 211:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pediconi F, Padula S, Dominelli V, et al. Role of breast MR imaging for predicting malignancy of histologically borderline lesions diagnosed at core needle biopsy: prospective evaluation. Radiology 2010; 257:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linda A, Zuiani C, Furlan A, et al. Nonsurgical management of high-risk lesions diagnosed at core needle biopsy: can malignancy be ruled out safely with breast MRI? AJR Am J Roentgenol 2012; 198:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Londero V, Zuiani C, Linda A, et al. High-risk breast lesions at imaging-guided needle biopsy: Usefulness of MRI for treatment decision. Am J Roentgenol 2012; 199:W240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller-Schimpfle M, Ohmenhaüser K, Stoll P, et al. Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast. Radiology 1997; 203:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delille JP, Slanetz PJ, Yeh ED, et al. Physiologic changes in breast magnetic resonance imaging during the menstrual cycle: perfusion imaging, signal enhancement, and influence of the T1 relaxation time of breast tissue. Breast J 2005; 11:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuhl CK, Bieling HB, Gieseke J, et al. Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. Radiology 1997; 203:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delille JP, Slanetz PJ, Yeh ED, et al. Hormone replacement therapy in postmenopausal women: breast tissue perfusion determined with MR imaging--initial observations. Radiology 2005; 235:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espinosa LA, Daniel BL, Vidarsson L, et al. The lactating breast: contrast-enhanced MR imaging of normal tissue and cancer. Radiology 2005; 237:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talele AC, Slanetz PJ, Edmister WB, et al. The lactating breast: MRI findings and literature review. Breast J 2003; 9:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuhl C. The current status of breast MR imaging. Part I. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice. Radiology 2007; 244:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitehouse GH, Moore NR. MR imaging of the breast after surgery for breast cancer. Magn Reson Imaging Clin N Am 1994; 2:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dixon JM, Renshaw L, Bellamy C, et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res 2000; 6:2229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor C, Georgian-Smith D. Regression of breast cancer in four patients treated with tamoxifen: mammographic features. AJR Am J Roentgenol 1994; 162:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schrading S, Schild H, Kühr M, Kuhl C. Effects of tamoxifen and aromatase inhibitors on breast tissue enhancement in dynamic contrast-enhanced breast MR imaging: a longitudinal intraindividual cohort study. Radiology 2014; 271:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Orsi CJ, Newell MS. BI-RADS decoded: detailed guidance on potentially confusing issues. Radiol Clin North Am 2007; 45:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bassett LW, Dhaliwal SG, Eradat J, et al. National trends and practices in breast MRI. AJR Am J Roentgenol 2008; 191:332.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Breast cancer screening and diagnosis. https://www.nccn.org/professionals/physician_gls/pdf/breast-screening.pdf.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teifke A, Lehr HA, Vomweg TW, et al. Outcome analysis and rational management of enhancing lesions incidentally detected on contrast-enhanced MRI of the breast. AJR Am J Roentgenol 2003; 181:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Millet I, Curros-Doyon F, Molinari N, et al. Invasive breast carcinoma: influence of prognosis and patient-related factors on kinetic MR imaging characteristics. Radiology 2014; 270:57.
          </a>
         </li>
         <li class="breakAll">
          MRISafety.com http://www.mrisafety.com/ (Accessed on March 30, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorczyca DP, Gorczyca SM, Gorczyca KL. The diagnosis of silicone breast implant rupture. Plast Reconstr Surg 2007; 120:49S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berg WA, Caskey CI, Hamper UM, et al. Diagnosing breast implant rupture with MR imaging, US, and mammography. Radiographics 1993; 13:1323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Everson LI, Parantainen H, Detlie T, et al. Diagnosis of breast implant rupture: imaging findings and relative efficacies of imaging techniques. AJR Am J Roentgenol 1994; 163:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reynolds HE, Buckwalter KA, Jackson VP, et al. Comparison of mammography, sonography, and magnetic resonance imaging in the detection of silicone-gel breast implant rupture. Ann Plast Surg 1994; 33:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown SL, Silverman BG, Berg WA. Rupture of silicone-gel breast implants: causes, sequelae, and diagnosis. Lancet 1997; 350:1531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson OG Jr, Bradley EL, Wilson DS. Analysis of explanted silicone implants: a report of 300 patients. Ann Plast Surg 1995; 34:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCarthy CM, Pusic AL, Kerrigan CL. Silicone breast implants and magnetic resonance imaging screening for rupture: do U.S. Food and Drug Administration recommendations reflect an evidence-based practice approach to patient care? Plast Reconstr Surg 2008; 121:1127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cher DJ, Conwell JA, Mandel JS. MRI for detecting silicone breast implant rupture: meta-analysis and implications. Ann Plast Surg 2001; 47:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huch RA, Künzi W, Debatin JF, et al. MR imaging of the augmented breast. Eur Radiol 1998; 8:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scaranelo AM, de Fátima Ribeiro Maia M. Sonographic and mammographic findings of breast liquid silicone injection. J Clin Ultrasound 2006; 34:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stomper PC, Waddell BE, Edge SB, Klippenstein DL. Breast MRI in the Evaluation of Patients with Occult Primary Breast Carcinoma. Breast J 1999; 5:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orel SG, Weinstein SP, Schnall MD, et al. Breast MR imaging in patients with axillary node metastases and unknown primary malignancy. Radiology 1999; 212:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buchanan CL, Morris EA, Dorn PL, et al. Utility of breast magnetic resonance imaging in patients with occult primary breast cancer. Ann Surg Oncol 2005; 12:1045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olson JA Jr, Morris EA, Van Zee KJ, et al. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol 2000; 7:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen C, Orel SG, Harris E, et al. Outcome after treatment of patients with mammographically occult, magnetic resonance imaging-detected breast cancer presenting with axillary lymphadenopathy. Clin Breast Cancer 2004; 5:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obdeijn IM, Brouwers-Kuyper EM, Tilanus-Linthorst MM, et al. MR imaging-guided sonography followed by fine-needle aspiration cytology in occult carcinoma of the breast. AJR Am J Roentgenol 2000; 174:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schorn C, Fischer U, Luftner-Nagel S, et al. MRI of the breast in patients with metastatic disease of unknown primary. Eur Radiol 1999; 9:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henry-Tillman RS, Harms SE, Westbrook KC, et al. Role of breast magnetic resonance imaging in determining breast as a source of unknown metastatic lymphadenopathy. Am J Surg 1999; 178:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tilanus-Linthorst MM, Obdeijn AI, Bontenbal M, Oudkerk M. MRI in patients with axillary metastases of occult breast carcinoma. Breast Cancer Res Treat 1997; 44:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brenner RJ, Rothman BJ. Detection of primary breast cancer in women with known adenocarcinoma metastatic to the axilla: use of MRI after negative clinical and mammographic examination. J Magn Reson Imaging 1997; 7:1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris EA, Schwartz LH, Dershaw DD, et al. MR imaging of the breast in patients with occult primary breast carcinoma. Radiology 1997; 205:437.
          </a>
         </li>
         <li class="breakAll">
          Fourquet, A, Meunier, et al. Occult primary cancer with axillary metastases. In: Diseases of the Breast, 3rd ed, Harris, JR, Lippman, ME, Morrow, M, Osborne, CK (Eds), Lippincott, Williams and Wilkins, Philadelphia 2004. p.1047.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaiser WA, Zeitler E. MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. Radiology 1989; 170:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Revel D, Brasch RC, Paajanen H, et al. Gd-DTPA contrast enhancement and tissue differentiation in MR imaging of experimental breast carcinoma. Radiology 1986; 158:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heywang SH, Wolf A, Pruss E, et al. MR imaging of the breast with Gd-DTPA: use and limitations. Radiology 1989; 171:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stack JP, Redmond OM, Codd MB, et al. Breast disease: tissue characterization with Gd-DTPA enhancement profiles. Radiology 1990; 174:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orel SG, Schnall MD, LiVolsi VA, Troupin RH. Suspicious breast lesions: MR imaging with radiologic-pathologic correlation. Radiology 1994; 190:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liberman L, Morris EA, Dershaw DD, et al. MR imaging of the ipsilateral breast in women with percutaneously proven breast cancer. AJR Am J Roentgenol 2003; 180:901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schelfout K, Van Goethem M, Kersschot E, et al. Contrast-enhanced MR imaging of breast lesions and effect on treatment. Eur J Surg Oncol 2004; 30:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischer U, Kopka L, Grabbe E. Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic approach. Radiology 1999; 213:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mumtaz H, Hall-Craggs MA, Davidson T, et al. Staging of symptomatic primary breast cancer with MR imaging. AJR Am J Roentgenol 1997; 169:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schnall MD, Blume J, Bluemke DA, et al. MRI detection of distinct incidental cancer in women with primary breast cancer studied in IBMC 6883. J Surg Oncol 2005; 92:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Houssami N, Turner R, Macaskill P, et al. An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrence. J Clin Oncol 2014; 32:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gommers JJJ, Duijm LEM, Bult P, et al. The Impact of Preoperative Breast MRI on Surgical Margin Status in Breast Cancer Patients Recalled at Biennial Screening Mammography: An Observational Cohort Study. Ann Surg Oncol 2021; 28:5929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang SY, Kuntz KM, Tuttle TM, et al. The association of preoperative breast magnetic resonance imaging and multiple breast surgeries among older women with early stage breast cancer. Breast Cancer Res Treat 2013; 138:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hawley ST, Jagsi R, Morrow M, et al. Social and clinical determinants of contralateral prophylactic mastectomy. JAMA Surg 2014; 149:582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chandwani S, George PA, Azu M, et al. Role of preoperative magnetic resonance imaging in the surgical management of early-stage breast cancer. Ann Surg Oncol 2014; 21:3473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xia C, Schroeder MC, Weigel RJ, et al. Rate of contralateral prophylactic mastectomy is influenced by preoperative MRI recommendations. Ann Surg Oncol 2014; 21:4133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rahbar H, Hanna LG, Gatsonis C, et al. Contralateral prophylactic mastectomy in the American College of Radiology Imaging Network 6667 trial: effect of breast MR imaging assessments and patient characteristics. Radiology 2014; 273:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guilfoyle C, Christoudias M, Collett AE, et al. Effect of preoperative MRI on mastectomy and contralateral prophylactic mastectomy rates at a community hospital by a single surgeon. Breast J 2014; 20:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martincich L, Montemurro F, De Rosa G, et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 2004; 83:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pickles MD, Lowry M, Manton DJ, et al. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 2005; 91:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeh E, Slanetz P, Kopans DB, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol 2005; 184:868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheung YC, Chen SC, Su MY, et al. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast Cancer Res Treat 2003; 78:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martincich L, Montemurro F, Cirillo S, et al. Role of Magnetic Resonance Imaging in the prediction of tumor response in patients with locally advanced breast cancer receiving neoadjuvant chemo-therapy. Radiol Med 2003; 106:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi BB, Kim SH. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy. Acta Radiol 2015; 56:790.
          </a>
         </li>
         <li class="breakAll">
          Magnetic resonance imaging in women receiving chemotherapy for stage III breast cancer (ACRIN 6657). http://clinicaltrials.gov/ct2/show/NCT00043017 (Accessed on July 30, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viehweg P, Heinig A, Lampe D, et al. Retrospective analysis for evaluation of the value of contrast-enhanced MRI in patients treated with breast conservative therapy. MAGMA 1998; 7:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drew PJ, Kerin MJ, Turnbull LW, et al. Routine screening for local recurrence following breast-conserving therapy for cancer with dynamic contrast-enhanced magnetic resonance imaging of the breast. Ann Surg Oncol 1998; 5:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rieber A, Merkle E, Zeitler H, et al. Value of MR mammography in the detection and exclusion of recurrent breast carcinoma. J Comput Assist Tomogr 1997; 21:780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Goethem M, Verslegers I, Biltjes I, et al. Role of MRI of the breast in the evaluation of the symptomatic patient. Curr Opin Obstet Gynecol 2009; 21:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinstein S, Rosen M. Breast MR imaging: current indications and advanced imaging techniques. Radiol Clin North Am 2010; 48:1013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cilotti A, Iacconi C, Marini C, et al. Contrast-enhanced MR imaging in patients with BI-RADS 3-5 microcalcifications. Radiol Med 2007; 112:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakahara H, Namba K, Watanabe R, et al. A comparison of MR imaging, galactography and ultrasonography in patients with nipple discharge. Breast Cancer 2003; 10:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mortellaro VE, Marshall J, Harms SE, et al. Breast MR for the evaluation of occult nipple discharge. Am Surg 2008; 74:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballesio L, Maggi C, Savelli S, et al. Role of breast magnetic resonance imaging (MRI) in patients with unilateral nipple discharge: preliminary study. Radiol Med 2008; 113:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tokuda Y, Kuriyama K, Nakamoto A, et al. Evaluation of suspicious nipple discharge by magnetic resonance mammography based on breast imaging reporting and data system magnetic resonance imaging descriptors. J Comput Assist Tomogr 2009; 33:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morrogh M, Morris EA, Liberman L, et al. The predictive value of ductography and magnetic resonance imaging in the management of nipple discharge. Ann Surg Oncol 2007; 14:3369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sardanelli F, Podo F, D'Agnolo G, et al. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. Radiology 2007; 242:698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lehman CD, Isaacs C, Schnall MD, et al. Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology 2007; 244:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005; 23:8469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004; 292:1317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris EA, Liberman L, Ballon DJ, et al. MRI of occult breast carcinoma in a high-risk population. AJR Am J Roentgenol 2003; 181:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rijnsburger AJ, Obdeijn IM, Kaas R, et al. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol 2010; 28:5265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo G, Scaranelo AM, Aboras H, et al. Evaluation of the Utility of Screening Mammography for High-Risk Women Undergoing Screening Breast MR Imaging. Radiology 2017; 285:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riedl CC, Luft N, Bernhart C, et al. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. J Clin Oncol 2015; 33:1128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiarelli AM, Blackmore KM, Muradali D, et al. Performance Measures of Magnetic Resonance Imaging Plus Mammography in the High Risk Ontario Breast Screening Program. J Natl Cancer Inst 2020; 112:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heacock L, Melsaether AN, Heller SL, et al. Evaluation of a known breast cancer using an abbreviated breast MRI protocol: Correlation of imaging characteristics and pathology with lesion detection and conspicuity. Eur J Radiol 2016; 85:815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuhl CK, Schrading S, Strobel K, et al. Abbreviated breast magnetic resonance imaging (MRI): first postcontrast subtracted images and maximum-intensity projection-a novel approach to breast cancer screening with MRI. J Clin Oncol 2014; 32:2304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harvey SC, Di Carlo PA, Lee B, et al. An Abbreviated Protocol for High-Risk Screening Breast MRI Saves Time and Resources. J Am Coll Radiol 2016; 13:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panigrahi B, Mullen L, Falomo E, et al. An Abbreviated Protocol for High-risk Screening Breast Magnetic Resonance Imaging: Impact on Performance Metrics and BI-RADS Assessment. Acad Radiol 2017; 24:1132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen SQ, Huang M, Shen YY, et al. Application of Abbreviated Protocol of Magnetic Resonance Imaging for Breast Cancer Screening in Dense Breast Tissue. Acad Radiol 2017; 24:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi BH, Choi N, Kim MY, et al. Usefulness of abbreviated breast MRI screening for women with a history of breast cancer surgery. Breast Cancer Res Treat 2018; 167:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinstein SP, Korhonen K, Cirelli C, et al. Abbreviated Breast Magnetic Resonance Imaging for Supplemental Screening of Women With Dense Breasts and Average Risk. J Clin Oncol 2020; 38:3874.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewin JM, Isaacs PK, Vance V, Larke FJ. Dual-energy contrast-enhanced digital subtraction mammography: feasibility. Radiology 2003; 229:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fallenberg EM, Dromain C, Diekmann F, et al. Contrast-enhanced spectral mammography versus MRI: Initial results in the detection of breast cancer and assessment of tumour size. Eur Radiol 2014; 24:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jochelson MS, Dershaw DD, Sung JS, et al. Bilateral contrast-enhanced dual-energy digital mammography: feasibility and comparison with conventional digital mammography and MR imaging in women with known breast carcinoma. Radiology 2013; 266:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheung YC, Lin YC, Wan YL, et al. Diagnostic performance of dual-energy contrast-enhanced subtracted mammography in dense breasts compared to mammography alone: interobserver blind-reading analysis. Eur Radiol 2014; 24:2394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sardanelli F, Fausto A, Di Leo G, et al. In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy. AJR Am J Roentgenol 2009; 192:1608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartella L, Thakur SB, Morris EA, et al. Enhancing nonmass lesions in the breast: evaluation with proton (1H) MR spectroscopy. Radiology 2007; 245:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geraghty PR, van den Bosch MA, Spielman DM, et al. MRI and (1)H MRS of the breast: presence of a choline peak as malignancy marker is related to K21 value of the tumor in patients with invasive ductal carcinoma. Breast J 2008; 14:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mountford C, Ramadan S, Stanwell P, Malycha P. Proton MRS of the breast in the clinical setting. NMR Biomed 2009; 22:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tozaki M, Sakamoto M, Oyama Y, et al. Monitoring of early response to neoadjuvant chemotherapy in breast cancer with (1)H MR spectroscopy: comparison to sequential 2-[18F]-fluorodeoxyglucose positron emission tomography. J Magn Reson Imaging 2008; 28:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belli P, Costantini M, Bufi E, et al. Diffusion-weighted imaging in breast lesion evaluation. Radiol Med 2010; 115:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guo Y, Cai YQ, Cai ZL, et al. Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J Magn Reson Imaging 2002; 16:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinha S, Lucas-Quesada FA, Sinha U, et al. In vivo diffusion-weighted MRI of the breast: potential for lesion characterization. J Magn Reson Imaging 2002; 15:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palle L, Reddy B. Role of diffusion MRI in characterizing benign and malignant breast lesions. Indian J Radiol Imaging 2009; 19:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tozaki M, Fukuma E. 1H MR spectroscopy and diffusion-weighted imaging of the breast: are they useful tools for characterizing breast lesions before biopsy? AJR Am J Roentgenol 2009; 193:840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim SH, Cha ES, Kim HS, et al. Diffusion-weighted imaging of breast cancer: correlation of the apparent diffusion coefficient value with prognostic factors. J Magn Reson Imaging 2009; 30:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pickles MD, Gibbs P, Lowry M, Turnbull LW. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 2006; 24:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma U, Danishad KK, Seenu V, Jagannathan NR. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed 2009; 22:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spick C, Pinker-Domenig K, Rudas M, et al. MRI-only lesions: application of diffusion-weighted imaging obviates unnecessary MR-guided breast biopsies. Eur Radiol 2014; 24:1204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khalkhali I, Villanueva-Meyer J, Edell SL, et al. Diagnostic accuracy of 99mTc-sestamibi breast imaging: multicenter trial results. J Nucl Med 2000; 41:1973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Connor M, Rhodes D, Hruska C. Molecular breast imaging. Expert Rev Anticancer Ther 2009; 9:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brem RF, Rapelyea JA, Zisman G, et al. Occult breast cancer: scintimammography with high-resolution breast-specific gamma camera in women at high risk for breast cancer. Radiology 2005; 237:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brem RF, Floerke AC, Rapelyea JA, et al. Breast-specific gamma imaging as an adjunct imaging modality for the diagnosis of breast cancer. Radiology 2008; 247:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brem RF, Petrovitch I, Rapelyea JA, et al. Breast-specific gamma imaging with 99mTc-Sestamibi and magnetic resonance imaging in the diagnosis of breast cancer--a comparative study. Breast J 2007; 13:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brem RF, Fishman M, Rapelyea JA. Detection of ductal carcinoma in situ with mammography, breast specific gamma imaging, and magnetic resonance imaging: a comparative study. Acad Radiol 2007; 14:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brem RF, Ioffe M, Rapelyea JA, et al. Invasive lobular carcinoma: detection with mammography, sonography, MRI, and breast-specific gamma imaging. AJR Am J Roentgenol 2009; 192:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou M, Johnson N, Gruner S, et al. Clinical utility of breast-specific gamma imaging for evaluating disease extent in the newly diagnosed breast cancer patient. Am J Surg 2009; 197:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weir L, Worsley D, Bernstein V. The value of FDG positron emission tomography in the management of patients with breast cancer. Breast J 2005; 11:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rousseau C, Devillers A, Sagan C, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 2006; 24:5366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cachin F, Prince HM, Hogg A, et al. Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy. J Clin Oncol 2006; 24:3026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avril N, Adler LP. F-18 fluorodeoxyglucose-positron emission tomography imaging for primary breast cancer and loco-regional staging. Radiol Clin North Am 2007; 45:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schöder H, Gönen M. Screening for cancer with PET and PET/CT: potential and limitations. J Nucl Med 2007; 48 Suppl 1:4S.
          </a>
         </li>
         <li class="breakAll">
          Fluoroestradiol F-18 injection. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212155s000lbl.pdf (Accessed on May 26, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Geel JJL, Boers J, Elias SG, et al. Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer. J Clin Oncol 2022; 40:3642.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 14972 Version 43.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3950145" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : MR imaging of the breast using gadolinium-DTPA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17392300" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21040870" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Breast MRI in community practice: equipment and imaging techniques at facilities in the Breast Cancer Surveillance Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17893062" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Perspectives on body MR imaging at ultrahigh field.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17893052" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Breast MR imaging at 3T.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19304726" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Increasing accuracy of detection of breast cancer with 3-T MRI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19652611" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : A combined high temporal and high spatial resolution 3 Tesla MR imaging protocol for the assessment of breast lesions: initial results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25742194" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28653648" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Gadolinium deposition in the brain: summary of evidence and recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8475297" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1947093" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Three-dimensional gadolinium-enhanced MR imaging of the breast: pulse sequence with fat suppression and magnetization transfer contrast. Work in progress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1853803" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Gadopentetate dimeglumine-enhanced chemical-shift MR imaging of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7972823" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7568850" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Benign and malignant breast lesions: differentiation with echo-planar MR imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15585733" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Magnetic resonance imaging of the breast prior to biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9212107" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Mapping pathophysiological features of breast tumors by MRI at high spatial resolution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10882243" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11505390" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Improved accuracy in differentiating malignant from benign mammographic abnormalities: a simple, improved magnetic resonance imaging method.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11505390" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Improved accuracy in differentiating malignant from benign mammographic abnormalities: a simple, improved magnetic resonance imaging method.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30625040" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Population-Based Assessment of the Association Between Magnetic Resonance Imaging Background Parenchymal Enhancement and Future Primary Breast Cancer Risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17851971" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Breast MRI in the evaluation of locally recurrent or new breast cancer in the postoperative patient: correlation of morphology and enhancement features with the BI-RADS category.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18941394" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A review of current evidence-based clinical applications for breast magnetic resonance imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20489110" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : False-positive findings at contrast-enhanced breast MRI: a BI-RADS descriptor study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10189459" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20884914" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Role of breast MR imaging for predicting malignancy of histologically borderline lesions diagnosed at core needle biopsy: prospective evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22268168" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Nonsurgical management of high-risk lesions diagnosed at core needle biopsy: can malignancy be ruled out safely with breast MRI?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : High-risk breast lesions at imaging-guided needle biopsy: Usefulness of MRI for treatment decision
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9122383" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15982388" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Physiologic changes in breast magnetic resonance imaging during the menstrual cycle: perfusion imaging, signal enhancement, and influence of the T1 relaxation time of breast tissue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9122382" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15798166" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Hormone replacement therapy in postmenopausal women: breast tissue perfusion determined with MR imaging--initial observations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16244250" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The lactating breast: contrast-enhanced MR imaging of normal tissue and cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12752635" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The lactating breast: MRI findings and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17641361" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The current status of breast MR imaging. Part I. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7489311" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : MR imaging of the breast after surgery for breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10873072" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8109507" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Regression of breast cancer in four patients treated with tamoxifen: mammographic features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24475835" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Effects of tamoxifen and aromatase inhibitors on breast tissue enhancement in dynamic contrast-enhanced breast MR imaging: a longitudinal intraindividual cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17888766" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : BI-RADS decoded: detailed guidance on potentially confusing issues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18647898" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : National trends and practices in breast MRI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18647898" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : National trends and practices in breast MRI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12933456" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Outcome analysis and rational management of enhancing lesions incidentally detected on contrast-enhanced MRI of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24029641" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Invasive breast carcinoma: influence of prognosis and patient-related factors on kinetic MR imaging characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24029641" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Invasive breast carcinoma: influence of prognosis and patient-related factors on kinetic MR imaging characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18090814" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The diagnosis of silicone breast implant rupture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8290727" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Diagnosing breast implant rupture with MR imaging, US, and mammography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8010248" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Diagnosis of breast implant rupture: imaging findings and relative efficacies of imaging techniques.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7985960" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Comparison of mammography, sonography, and magnetic resonance imaging in the detection of silicone-gel breast implant rupture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9388410" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Rupture of silicone-gel breast implants: causes, sequelae, and diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7702291" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Analysis of explanted silicone implants: a report of 300 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18349629" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Silicone breast implants and magnetic resonance imaging screening for rupture: do U.S. Food and Drug Administration recommendations reflect an evidence-based practice approach to patient care?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11601570" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : MRI for detecting silicone breast implant rupture: meta-analysis and implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9510568" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : MR imaging of the augmented breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16788958" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Sonographic and mammographic findings of breast liquid silicone injection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11348292" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Breast MRI in the Evaluation of Patients with Occult Primary Breast Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10429716" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Breast MR imaging in patients with axillary node metastases and unknown primary malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16244803" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Utility of breast magnetic resonance imaging in patients with occult primary breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10894136" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Magnetic resonance imaging facilitates breast conservation for occult breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15140289" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Outcome after treatment of patients with mammographically occult, magnetic resonance imaging-detected breast cancer presenting with axillary lymphadenopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10749254" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : MR imaging-guided sonography followed by fine-needle aspiration cytology in occult carcinoma of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10087118" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : MRI of the breast in patients with metastatic disease of unknown primary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10670860" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Role of breast magnetic resonance imaging in determining breast as a source of unknown metastatic lymphadenopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9232276" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : MRI in patients with axillary metastases of occult breast carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9400862" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Detection of primary breast cancer in women with known adenocarcinoma metastatic to the axilla: use of MRI after negative clinical and mammographic examination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9356625" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : MR imaging of the breast in patients with occult primary breast carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9356625" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : MR imaging of the breast in patients with occult primary breast carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2916021" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2417274" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Gd-DTPA contrast enhancement and tissue differentiation in MR imaging of experimental breast carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2648479" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : MR imaging of the breast with Gd-DTPA: use and limitations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2296657" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Breast disease: tissue characterization with Gd-DTPA enhancement profiles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8284404" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Suspicious breast lesions: MR imaging with radiologic-pathologic correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12646427" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : MR imaging of the ipsilateral breast in women with percutaneously proven breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15135477" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Contrast-enhanced MR imaging of breast lesions and effect on treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10580970" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9242745" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Staging of symptomatic primary breast cancer with MR imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16180227" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : MRI detection of distinct incidental cancer in women with primary breast cancer studied in IBMC 6883.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24395846" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33796997" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : The Impact of Preoperative Breast MRI on Surgical Margin Status in Breast Cancer Patients Recalled at Biennial Screening Mammography: An Observational Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23354364" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The association of preoperative breast magnetic resonance imaging and multiple breast surgeries among older women with early stage breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24849045" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Social and clinical determinants of contralateral prophylactic mastectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24912611" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Role of preoperative magnetic resonance imaging in the surgical management of early-stage breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24934585" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Rate of contralateral prophylactic mastectomy is influenced by preoperative MRI recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24937691" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Contralateral prophylactic mastectomy in the American College of Radiology Imaging Network 6667 trial: effect of breast MR imaging assessments and patient characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24438066" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Effect of preoperative MRI on mastectomy and contralateral prophylactic mastectomy rates at a community hospital by a single surgeon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14997056" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15868426" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15728611" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12611457" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12951551" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Role of Magnetic Resonance Imaging in the prediction of tumor response in patients with locally advanced breast cancer receiving neoadjuvant chemo-therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24951616" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24951616" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10050940" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Retrospective analysis for evaluation of the value of contrast-enhanced MRI in patients treated with breast conservative therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9607630" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Routine screening for local recurrence following breast-conserving therapy for cancer with dynamic contrast-enhanced magnetic resonance imaging of the breast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9294575" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Value of MR mammography in the detection and exclusion of recurrent breast carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19130631" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Role of MRI of the breast in the evaluation of the symptomatic patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20868898" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Breast MR imaging: current indications and advanced imaging techniques.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17361370" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Contrast-enhanced MR imaging in patients with BI-RADS 3-5 microcalcifications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14634510" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : A comparison of MR imaging, galactography and ultrasonography in patients with nipple discharge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18705577" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Breast MR for the evaluation of occult nipple discharge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18386126" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Role of breast magnetic resonance imaging (MRI) in patients with unilateral nipple discharge: preliminary study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19188786" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Evaluation of suspicious nipple discharge by magnetic resonance mammography based on breast imaging reporting and data system magnetic resonance imaging descriptors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17896158" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : The predictive value of ductography and magnetic resonance imaging in the management of nipple discharge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17244718" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17641362" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16293877" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15367553" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12933450" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : MRI of occult breast carcinoma in a high-risk population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15282350" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21079137" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28586291" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Evaluation of the Utility of Screening Mammography for High-Risk Women Undergoing Screening Breast MR Imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25713430" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31233143" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Performance Measures of Magnetic Resonance Imaging Plus Mammography in the High Risk Ontario Breast Screening Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26971429" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Evaluation of a known breast cancer using an abbreviated breast MRI protocol: Correlation of imaging characteristics and pathology with lesion detection and conspicuity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24958821" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Abbreviated breast magnetic resonance imaging (MRI): first postcontrast subtracted images and maximum-intensity projection-a novel approach to breast cancer screening with MRI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26521970" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : An Abbreviated Protocol for High-Risk Screening Breast MRI Saves Time and Resources.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28506511" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : An Abbreviated Protocol for High-risk Screening Breast Magnetic Resonance Imaging: Impact on Performance Metrics and BI-RADS Assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27916594" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Application of Abbreviated Protocol of Magnetic Resonance Imaging for Breast Cancer Screening in Dense Breast Tissue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29030785" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Usefulness of abbreviated breast MRI screening for women with a history of breast cancer surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32931396" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Abbreviated Breast Magnetic Resonance Imaging for Supplemental Screening of Women With Dense Breasts and Average Risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12888621" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Dual-energy contrast-enhanced digital subtraction mammography: feasibility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24048724" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Contrast-enhanced spectral mammography versus MRI: Initial results in the detection of breast cancer and assessment of tumour size.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23220903" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Bilateral contrast-enhanced dual-energy digital mammography: feasibility and comparison with conventional digital mammography and MR imaging in women with known breast carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24928280" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Diagnostic performance of dual-energy contrast-enhanced subtracted mammography in dense breasts compared to mammography alone: interobserver blind-reading analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19457825" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17885182" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Enhancing nonmass lesions in the breast: evaluation with proton (1H) MR spectroscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19000051" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : MRI and (1)H MRS of the breast: presence of a choline peak as malignancy marker is related to K21 value of the tumor in patients with invasive ductal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19086012" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Proton MRS of the breast in the clinical setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18666159" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Monitoring of early response to neoadjuvant chemotherapy in breast cancer with (1)H MR spectroscopy: comparison to sequential 2-[18F]-fluorodeoxyglucose positron emission tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19902330" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Diffusion-weighted imaging in breast lesion evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12203765" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12112520" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : In vivo diffusion-weighted MRI of the breast: potential for lesion characterization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19881104" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Role of diffusion MRI in characterizing benign and malignant breast lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19696300" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : 1H MR spectroscopy and diffusion-weighted imaging of the breast: are they useful tools for characterizing breast lesions before biopsy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19711411" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Diffusion-weighted imaging of breast cancer: correlation of the apparent diffusion coefficient value with prognostic factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16916701" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18384182" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24706105" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : MRI-only lesions: application of diffusion-weighted imaging obviates unnecessary MR-guided breast biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11138681" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Diagnostic accuracy of 99mTc-sestamibi breast imaging: multicenter trial results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19671027" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Molecular breast imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16126919" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Occult breast cancer: scintimammography with high-resolution breast-specific gamma camera in women at high risk for breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18487533" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Breast-specific gamma imaging as an adjunct imaging modality for the diagnosis of breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17760667" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Breast-specific gamma imaging with 99mTc-Sestamibi and magnetic resonance imaging in the diagnosis of breast cancer--a comparative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17659240" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Detection of ductal carcinoma in situ with mammography, breast specific gamma imaging, and magnetic resonance imaging: a comparative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19155397" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Invasive lobular carcinoma: detection with mammography, sonography, MRI, and breast-specific gamma imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19185109" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Clinical utility of breast-specific gamma imaging for evaluating disease extent in the newly diagnosed breast cancer patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15871707" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : The value of FDG positron emission tomography in the management of patients with breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17088570" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16717291" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17706529" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : F-18 fluorodeoxyglucose-positron emission tomography imaging for primary breast cancer and loco-regional staging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17204716" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Screening for cancer with PET and PET/CT: potential and limitations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17204716" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Screening for cancer with PET and PET/CT: potential and limitations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35584346" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
